BDM-2

BDM-2 is a small molecule allosteric inhibitor of HIV-1 integrase, specifically classified as an IN-LEDGF allosteric inhibitor (INLAI) or Allosteric Integrase Inhibitor (ALLINI). It blocks the interaction between the HIV integrase catalytic core domain and the host factor LEDGF/p75, thereby disrupting viral integration and maturation. BDM-2 exhibits potent anti-retroviral activity with an IC50 of 47 nM against HIV-1 integrase and demonstrates efficacy against viruses resistant to current antiretroviral drugs. Its dual mechanism includes weak inhibition at the integration step and strong antiviral effects during virus maturation. Preclinical studies have shown favorable pharmacology, toxicity profiles, and in vivo efficacy in humanized mouse models. Early clinical development has included phase 1 trials assessing safety, tolerability, and pharmacokinetics in healthy volunteers[1][3][4][5][7].

Other names

INLAI BDM-2